

An International Journal Specializing in
Environmental Mutagenesis

Volume 52
Number S1
October 2011

EMS Abstracts

Supplement to *Environmental and Molecular Mutagenesis*

MONTRÉAL
Q U É B E C
42nd Annual Meeting
October 15–19, 2011

Hilton
Montréal
Bonaventure

DETOUR
STE-CATHERINE
EMS

Environmental
Mutagen
Society

Environmental Impacts on
the Genome and Epigenome:
Mechanisms and Risks

In this issue: Abstracts from the Environmental Mutagen Society
42nd Annual Meeting, October 15–19, 2011, Montréal, Québec, Canada
Program Chair: Catherine B. Klein

Environmental and Molecular Mutagenesis

JOURNAL OF THE ENVIRONMENTAL MUTAGEN SOCIETY
OFFICERS, ENVIRONMENTAL MUTAGEN SOCIETY, 2010-2011

President
J. Schwartz

President-Elect
C. Klein

Past President
M. Plewa

Secretary
S. Morris

Treasurer
B. Shane

COUNCILORS

J. Baulch
J. Bielas
A. Buermeyer

K. Dobo
S. Dertinger
B. Engelward

P. Escobar
O. Kovalchuk
B. Mahadevan

F. Marchetti
O. Olivero
C. Somers

K. Vasquez
T. Wilson
K. Williams

P. White, Journal Editor

ASSOCIATE EDITOR

Iain Lambert
Carleton University
Ottawa, Ontario

EDITOR-IN-CHIEF

Paul White
Health Canada
Ottawa, Ontario

ASSOCIATE EDITOR

Carole Yauk
Health Canada
Ottawa, Ontario

EDITORIAL BOARD

Volker Arlt
Institute of Cancer Research
Sutton, United Kingdom

William M. Baird
Oregon State University
Corvallis, Oregon

Janet E. Baulch
University of Maryland School of Medicine
Baltimore, Maryland

Sonja I. Berndt
National Cancer Institute
Bethesda, Maryland

Stefano Bonassi
IRCCS San Raffaele Pisana
Rome, Italy

Sabit Cakmak
Health Canada
Ottawa, Ontario

Larry Claxton
IDC Scientific Services
Raleigh, North Carolina

Kerry L. Dearfield
U.S. Department of Agriculture
Washington, DC

David DeMarini
U.S. EPA
Research Triangle Park,
North Carolina

Azeddine Elhajouji
Novartis Pharma AG
Basel, Switzerland

James C. Fuscoe
FDA/NCTR
Jefferson, Arkansas

Sheila Galloway
Merck Research Laboratories
West Point, Pennsylvania

Robert Heflich
FDA/NCTR
Jefferson, Arkansas

George R. Hoffmann
Holy Cross College
Worcester, Massachusetts

Nina Holland
UC Berkeley
Berkeley, California

Masamitsu Honma
National Institute of Health Sciences
Tokyo, Japan

Catherine Klein
New York University School of Medicine
Tuxedo, New York

Andrew Kligerman
U.S. EPA
Research Triangle Park, North Carolina

Olga Kovalchuk
University of Lethbridge
Lethbridge, Alberta

Qing Lan
NCI
Bethesda, Maryland

Malcolm Lippert
Saint Michael's College
Colchester, Vermont

Francesco Marchetti
Health Canada
Ottawa, Ontario

Carlos Menck
Universidade de São Paulo
São Paulo, Brazil

Volker Mersch-Sundermann
Institute of Environmental Medicine and
Hospital Hygiene
Freiburg, Germany

William F. Morgan
Pacific Northwest National Laboratory
Richland, Washington

Hannu Norppa
Finnish Institute of Occupational Health
Helsinki, Finland

Barbara Parsons
FDA/NCTR
Jefferson, Arkansas

R. Julian Preston
U.S. EPA
Research Triangle Park,
North Carolina

Peter Schmezer
German Cancer Research Centre
Heidelberg, Germany

Michael D. Shelby
NIEHS
Research Triangle Park, North Carolina

Ronald D. Snyder
Schering-Plough Research Institute
Andover, New Jersey

Peter J. Stambrook
University of Cincinnati College of Medicine
Cincinnati, Ohio

Raymond R. Tice
NIEHS
Research Triangle Park, NC

Gisela Umbuzeiro
State University of Campinas – UNICAMP
São Paulo, Brazil

Jan Van Benthem
National Institute for Public Health and the
Environment (RIVM)
Bilthoven, The Netherlands

Karen Vasquez
University of Texas MD Anderson Cancer
Center
Smithville, Texas

Ulla Vogel
Technical University of Denmark
Søborg, Denmark

Vernon E. Walker
Biosmosics Inc.
Burlington, Vermont

David M. Wilson III
NIA
Baltimore, Maryland

Errol Zeiger
Errol Zeiger Consulting
Chapel Hill, North Carolina

© 2011 Wiley-Liss, Inc., a Wiley Company. All rights reserved. No part of this publication may be reproduced, stored or transmitted in any form or by any means without the prior permission in writing from the copyright holder. Authorization to photocopy items for internal and personal use is granted by the copyright holder for libraries and other users registered with their local Reproduction Rights Organisation (RRO), e.g. Copyright Clearance Center (CCC), 222 Rosewood Drive, Danvers, MA 01923, USA (www.copyright.com), provided the appropriate fee is paid directly to the RRO. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale. Special requests should be addressed to: permissionsuk@wiley.com.

ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (Print ISSN 0893-6692; Online ISSN 1098-2280 at Wiley Online Library, www.wileyonlinelibrary.com) is published monthly in January, March, April, May, June, July, August, October, December by Wiley-Liss, Inc., through Wiley Subscription Services, Inc., a Wiley Company, 111 River Street, Hoboken, NJ 07030. **Postmaster:** Send address changes to **ENVIRONMENTAL AND MOLECULAR MUTAGENESIS**, Journal Customer Services, John Wiley & Sons Inc., 350 Main St., Malden, MA 02148-5020. **Send subscription inquiries** c/o John Wiley & Sons, Inc., Attn: Journals Admin Dept UK, 111 River Street, Hoboken, NJ 07030, (201) 748-6645.

Offprint sales: Commercial Reprints: Email: corporatesalesusa@wiley.com; corporatesalesusa@wiley.com; or corporatesalesusa@wiley.com. **Author Reprints (50–500 copies):** Order online: <http://www.sheridanreprints.com/orderForm.html>; Email: cjones@tsp.sheridan.com. **Information for subscribers:** ENVIRONMENTAL AND MOLECULAR MUTAGENESIS is published in 9 issues per year. Institutional subscription prices for 2011 are: Print & Online: US\$1,410.00 (US), US\$1,536.00 (Canada/Mexico), US\$1,599.00 (Rest of World), €1,050.00 (Europe), £831.00 (UK). Prices are exclusive of tax. Asia-Pacific GST, Canadian GST and European VAT will be applied at the appropriate rates. For more information on current tax rates, please go to wileyonlinelibrary.com/tax-vat. The price includes online access to the current and all online back files to January 1st 2007, where available. For other pricing options, including access information and terms and conditions, please visit wileyonlinelibrary.com/access. **Delivery Terms and Legal Title:** Where the subscription price includes print issues and delivery is to the recipient's address, delivery terms are Delivered Duty Unpaid (DDU); the recipient is responsible for paying any import duty or taxes. Title to all issues transfers FOB our shipping point, freight prepaid. We will endeavour to fulfil claims for missing or damaged copies within six months of publication, within our reasonable discretion and subject to availability. **Journal Customer Services:** For ordering information, claims and any enquiry concerning your journal subscription please go to www.wileycustomerhelp.com/ask or contact your nearest office: **Americas:** Email: cs-journals@wiley.com; Tel: +1 781 388 8598 or 1 800 835 6770 (Toll free in the USA & Canada); **Europe, Middle East and Africa:** Email: cs-journals@wiley.com; Tel: +44 (0) 1865 778315; **Asia Pacific:** Email: cs-journals@wiley.com; Tel: +65 6511 8000. **Japan:** For Japanese-speaking support, Email: cs-japan@wiley.com; Tel (toll-free): 005 316 50 480. Further Japanese customer support is also available at wileyonlinelibrary.com. **Visit our Online Customer Self-Help** available in 7 languages at www.wileycustomerhelp.com. **All Subscribers:** Claims cannot be honored beyond four months after mailing date. Duplicate copies cannot be sent to replace issues not delivered because of failure to notify publisher of change of address. **Cancellations:** Subscription cancellations will not be accepted after the first issue has been mailed. Environmental and Molecular Mutagenesis accepts articles for Open Access publication. Please visit <http://olabout.wiley.com/WileyCDA/Section/id-406241.html> for further information about OnlineOpen. **Back issues:** Single issues from current and recent volumes are available at the current single issue price from cs-journals@wiley.com. Earlier issues may be obtained from Periodicals Service Company, 11 Main Street, Germantown, NY 12526, USA. Tel: +1 518 537 4700. Fax: +1 518 537 5899. Email: psc@periodicals.com. **Wiley's Corporate Citizenship** initiative seeks to address the environmental, social, economic, and ethical challenges faced in our business and which are important to our diverse stakeholder groups. Since launching the initiative, we have focused on sharing our content with those in need, enhancing community philanthropy, reducing our carbon impact, creating global guidelines and best practices for paper use, establishing a vendor code of ethics, and engaging our colleagues and other stakeholders in our efforts. Follow our progress at www.wiley.com/go/citizenship. **Indexed by:** AGRICOLA Database (National Agricultural Library) • ASFA: Aquatic Sciences & Fisheries Abstracts (CSA/CIG) • BIOBASE (Elsevier) • Biological Abstracts® (Thomson ISI) • BIOSIS Previews® (Thomson ISI) • Biotechnology & Bioengineering Abstracts (CSA/CIG) • CAB Abstracts® (CABI) • Cambridge Scientific Abstracts (CSA/CIG) • Chemical Abstracts Service/SciFinder (ACS) • Chemical Hazards in Industry (RSC) • Chemical Safety NewsBase (RSC) • Chmicha Database (Elsevier) • CSA Biological Sciences Database (CSA/CIG) • CSA Environmental Sciences & Pollution Management Database (CSA/CIG) • Current Awareness in Biological Sciences (Elsevier) • Current Contents®/Life Sciences (Thomson ISI) • EMBASE/Excerpta Medica (Elsevier) • Index Medicus/MEDLINE/PubMed (NLM) • Journal Citation Reports/Science Edition (Thomson ISI) • Laboratory Hazards Bulletin (RSC) • MDL Beilstein (Elsevier) • PASCAL Database (INIST/CNRS) • Reference Update (Thomson ISI) • Science Citation Index Expanded™ (Thomson ISI) • Science Citation Index® (Thomson ISI) • SCOPUS (Elsevier) • VINITI (All-Russian Institute of Science & Technological Information) • Web of Science® (Thomson ISI). For submission instructions, subscription and all other information visit: wileyonlinelibrary.com/em. **Disclaimer:** The Publisher and Editors cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; the views and opinions expressed do not necessarily reflect those of the Publisher and Editors, neither does the publication of advertisements constitute any endorsement by the Publisher and Editors of the products advertised. Printed in the United States of America by Cadmus Communications, a Cenveo company.

This journal is printed on acid-free paper.

© Copyright 2011 Wiley-Liss, Inc.

EMS Abstracts

Supplement of *Environmental and Molecular Mutagenesis*

JOURNAL OF THE ENVIRONMENTAL MUTAGEN SOCIETY

Volume 52, Number S1	2011
Annual Meeting Agenda	S2
Plenary Lecture Abstracts	S13
Public Lecture Abstract	S14
Symposium Abstracts	S14
Special Interest Group Abstracts	S34
Platform Abstracts	S37
Poster Abstracts	S41
Author Index	S83

Volume 52, Number S1, was posted the week of October 3, 2011.

**ENVIRONMENTAL MUTAGEN SOCIETY
42ND ANNUAL MEETING**

**Environmental Impacts on
the Genome and Epigenome:
Mechanisms and Risks**

October 15–19, 2011

**Hilton Montréal Bonaventure
Montréal, Québec, Canada**

Program Chair: Catherine B. Klein, Ph.D.

EMS Headquarters
1821 Michael Faraday Drive, Suite 300
Reston, VA 20190

Telephone: 703.438.8220 Fax: 703.438.3113
E-mail: emshq@ems-us.org
Web site: www.ems-us.org

S58

Preventing Occupational Exposures to Antineoplastic Drugs in Health Care Settings. Connor TH, National Institute for Occupational Safety and Health, Cincinnati, OH, United States.

Introduction: Occupational exposure to antineoplastic drugs has been a concern of healthcare professionals since the 1970s following reports of secondary cancers in patients treated with these drugs. The detection of mutagens in the urine of nurses first alerted healthcare professionals to the potential for exposure to antineoplastic drugs in the workplace. Since many of the anti-cancer drugs cause DNA damage, properly designed tests for genotoxicity can reflect exposure to these drugs. Methods: Peer-reviewed articles dealing with biomarkers of genotoxic damage associated with occupational exposure to antineoplastic drugs published between 1990 and 2011 were reviewed. The studies employed various types of assays for biomarkers of genotoxicity. In addition to urine mutagenicity, biomarkers included chromosomal aberrations, sister chromatid exchanges, induction of micronuclei and DNA damage, plus several miscellaneous endpoints. Results: During this period, 99 studies were identified that evaluated differences in biomarkers of genotoxic damage in healthcare workers as compared to matched control groups. The majority of the studies was cross-sectional in design and often had the limitation of small sample size. Some studies evaluated interventions aimed at reducing exposure to these drugs. Approximately two-thirds of the studies reported an association between occupational exposure to antineoplastic drugs and the biomarker of genotoxicity. In most studies, interventions reduced the frequency of genotoxic damage. Discussion: Although the long-term consequences of the exposure to antineoplastic drugs are not fully understood, given their genotoxic potential, efforts should be undertaken to reduce potential exposure to these drugs in the workplace.

Symposium 13—Using DNA Adducts in Risk Assessment: Approaches, Considerations, and Significance

S59

ILSI/HESI DNA Adducts Project Committee: Review of Case Study Outcomes: Tamoxifen, AFB₁, and VCI. Pottenger LH, The Dow Chemical Company, Midland, MI, United States.

The biological significance and role of DNA adduct data in risk assessment are debated. An ILSI/HESI Committee published a systematic approach for the evaluation of DNA adduct data in a key event dose-response framework for a mutagenic mode-of-action (MOA) analysis for cancer risk. The approach stresses the need to create a context for adduct data in conjunction with other key types of data such as dosimetry, mechanistic response data, and tumor incidence. This systematic approach was applied to data for three chemicals to illustrate its use: aflatoxin B₁, tamoxifen, and vinyl chloride. These chemicals presented a variety of characteristics and some specific challenges for adduct data interpretation, such as presence of background/endogenous adducts, different MOAs for rodents vs. humans, and data quality and reliability. Analysis of these case studies led to a set of general principles for evaluating the role of DNA adduct data in the MOA, including the following: Target tissue and adduct type depend on exposure concentration, duration, and internal dose determinants such as physico-chemical properties, anatomical and physiological factors, and ADME processes. Adduct profiles can change with duration or dose, due to differences in repair/persistence of specific adducts. Both characterization and structural identification are necessary for DNA adduct use in MOA assessment. Key conclusions include the following: DNA adduct data cannot be used in isolation to determine a mutagenic MOA; DNA adducts represent biomarkers of exposure and not of effect; and DNA adduct data alone are informative but not sufficient to assign a mutagenic MOA.

S60

Application of a Decision Analytic Approach to Case Studies. Jarabek AM, U.S. EPA, National Center for Environmental Assessment, Research Triangle Park, NC, United States.

Recent assessment approaches use weight of evidence and human relevance frameworks to evaluate evidence on the mode of action (MOA) for a chemical. To date, what is often lacking is an explicit expression of data quality, utility, and reliability to support claims of causality for a given key event(s). This expression is important because judgments concerning data on parameters for specific steps influence the confidence in the ultimate decision regarding causality. A two-step decision analytic approach to evaluate causality is proposed. The 1st step is to populate a conceptual MOA model with specific data on parameters. Description of the pathogenesis process is divided into characterization of two key components: dosimetry (toxicokinetics) and response (toxicodynamics). The 2nd step entails evaluating both the ability of the data to describe or represent the particular parameter or process, and the extrapolation premises or assumptions required to apply these data to the human disease target context. This requires explicit evaluation of the data from various observational contexts: *in vitro*, *in vivo* laboratory animal and human studies. Data are assigned to evidence categories (direct empirical, semi-empirical, empirical correlation or theory-based inference) to assess relevance. Coherence of data within an observational context and then across contexts is used to arrive at a summary judgment of causality for each of the two characterizations. These are combined to arrive at overall confidence in the conclusion regarding the causal role of the proposed key event(s). (These views are those of the author and do not represent U.S. EPA policy).

S61

Mutagenesis and Repair of O⁶- and N7-Alkylguanine DNA Adducts. Fuchs RP¹, Mazon G¹, Modesti M¹, Phillipin G¹, Gasparutto D², Cadet J². ¹CNRS, UPR 3081, Marseille, France, ²CEA, LAN, Grenoble, France.

The mutagenicity of O⁶- and N7-alkylguanine adducts formed by ethylene oxide (EO) and propylene oxide (PO) was investigated by the use of single-adducted plasmids. N7-alkylguanine adducts were found to be intrinsically non-mutagenic provided the apurinic sites that may form spontaneously are removed prior to introduction of the plasmids into cells. In contrast, O⁶-alkylG adducts are highly mutagenic due to their capacity to efficiently mispair with T during replication, triggering G->A transitions. For these lesions, mutagenesis is largely prevented by repair strategies *via* alkyltransferases (AT) or Nucleotide Excision Repair (NER) pathways. Recently, we have shown that the alkyltransferase-like gene *ybaZ* (eATL) enhances repair of these adducts by Nucleotide Excision Repair. In addition, methyl-directed Mismatch Repair (MMR) is known to trigger sensitivity to methylating agents *via* a mechanism that involves recognition by MutS of the O⁶-mG:T replication intermediates. We show that eATL prevents MMR-mediated attack of the O⁶-alkylG:T replication intermediate for the larger alkyl groups but not for methyl. *In vivo* data are compatible with the occurrence of repeated cycles of MMR attack of the O⁶-alkylG:T intermediate. *In vitro*, the eATL protein efficiently prevents binding of MutS to the O⁶-alkylG:T mispairs formed by the larger alkyl groups but not by methyl. In conclusion, eATL not only enhances the efficiency of repair of these larger, O⁶-alkylG adducts by NER, but it also shields these adducts from MMR-mediated toxicity. This is the first report demonstrating the lack of intrinsic mutagenic effect by N7-alkylG adducts induced by EO or PO.